Enanta Pharmaceuticals (ENTA) EBT Margin (2016 - 2025)
Historic EBT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 64.0%.
- Enanta Pharmaceuticals' EBT Margin rose 698900.0% to 64.0% in Q4 2025 from the same period last year, while for Dec 2025 it was 108.62%, marking a year-over-year increase of 512500.0%. This contributed to the annual value of 127.9% for FY2025, which is 462500.0% up from last year.
- Per Enanta Pharmaceuticals' latest filing, its EBT Margin stood at 64.0% for Q4 2025, which was up 698900.0% from 123.42% recorded in Q3 2025.
- In the past 5 years, Enanta Pharmaceuticals' EBT Margin ranged from a high of 64.0% in Q4 2025 and a low of 211.37% during Q1 2023
- In the last 5 years, Enanta Pharmaceuticals' EBT Margin had a median value of 149.66% in 2021 and averaged 149.11%.
- Its EBT Margin has fluctuated over the past 5 years, first plummeted by -1088800bps in 2021, then skyrocketed by 763800bps in 2025.
- Enanta Pharmaceuticals' EBT Margin (Quarter) stood at 109.05% in 2021, then decreased by -13bps to 123.04% in 2022, then tumbled by -54bps to 189.02% in 2023, then grew by 29bps to 133.89% in 2024, then soared by 52bps to 64.0% in 2025.
- Its last three reported values are 64.0% in Q4 2025, 123.42% for Q3 2025, and 99.52% during Q2 2025.